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Propionibacterium acnes is the only microorganism isolated from sarcoid lesions by bacterial
culture. Numerous P. acnes genomes are found in lymph node samples from Japanese and
European patients with sarcoidosis, whereas a few genomes are found in some
non-sarcoid samples. The high frequency and specificity of detecting P. acnes within
sarcoid granulomas suggests that this indigenous bacterium causes granuloma formation
in many patients with sarcoidosis. P. acnes is the most common commensal bacterium
in the lungs and lymph nodes. Occasional detection of P. acnes in non-granulomatous areas
of these organs from non-sarcoid patients suggests that host factors are more critical than
agent factors in the etiology of sarcoidosis. A particular protein, i.e., trigger factor, from
P. acnes causes a cellular immune response only in sarcoid patients. The P. acnes trigger-
factor protein induces pulmonary granulomas in mice sensitized with the protein and
adjuvant, but only in those with latent P. acnes infection in their lungs. Eradication of
P. acnes by antibiotics prevents the development of granulomas in this experimental model.
P. acnes can cause latent infection in the lung and lymph nodes and persists in a cell wall-
deficient form. The dormant form is endogenously activated under certain conditions and
proliferates at the site of latent infection. In patients with P. acnes hypersensitivity,
granulomatous inflammation is triggered by intracellular proliferation of the bacterium.
Proliferating bacteria may escape granulomatous isolation, spreading to other organs.
Latent P. acnes infection in systemic organs can be reactivated by another triggering event,
leading to systemic sarcoidosis.
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Sarcoidosis is one of the best-studied systemic granuloma-
tous diseases. Despite intensive investigation, however, the
etiology of sarcoidosis has remained unresolved for more
than 100 years [1]. Sarcoidosis seems to result from the
exposure of a genetically susceptible subject to an environ-
mental agent, and microbial etiologies of sarcoidosis have
long been considered because of the clinical similarities to
infectious granulomatous diseases [2]. Several epidemiologic
mechanisms may underlie the association of an infective
agent or agents with the etiology of sarcoidosis, including
spatial, seasonal, and occupational clustering [3]. The results
of A Case Control Etiologic Study of Sarcoidosis (ACCESS)
study support an association between selected microbially
rich environments and sarcoidosis [4].
Mycobacterial and propionibacterial organisms are the
most commonly implicated etiologic agents based on studies
indicating the detection, by polymerase chain reaction (PCR),
of microbial DNA from these organisms in tissues from
sarcoid patients around the world [5–7]. Different studies
have produced considerably varying results, however, with
microbial DNA detected in 0–80% of sarcoidosis tissues and in
0% to more than 30% of control tissues [8,9]. The failure to
detect microbial DNA from these organisms in samples from
some sarcoid patients suggests other causes of sarcoidosis in
those patients, whereas detection of microbial DNA in some
control samples suggests latent infection of the bacterium.
Immune responses against microbial antigens from these
organisms, e.g., ESAT-6 and KatG peptides from Mycobacterium
tuberculosis and a recombinant trigger-factor protein from
Propionibacterium acnes, have been examined in sarcoid patients
and control subjects [10,11]. Immune responses are frequently
detected in sarcoid patients, as well as in some non-sarcoid
patients and healthy subjects. Latent infection by these organ-
isms complicates the interpretation of the results of these
immunologic studies. Unless microbial antigens, which cause
a specific immune response found only in sarcoid patients, can
be used to stimulate an immune response, immunologic
approaches will not be sufficient to unequivocally confirm that
these organisms are causative.
Granuloma formation results from the persistence of a
non-degradable product or a hypersensitivity response [12].
The two mechanisms overlap in most infectious diseases
because microorganisms act as both foreign bodies and
antigens to induce immunologic responses. Granulomas
serve as a protective mechanism to sequester and degrade
the invading agent. The pathologic hallmark of sarcoidosis is
an epithelioid cell granuloma; thus, some etiologic agent of
sarcoidosis must be present or has been present within the
sarcoid granuloma. Histopathological studies are thereforeessential to demonstrate mycobacterial or propionibacterial
organisms or antigens within sarcoid granulomas to establish
an etiologic link between sarcoidosis and these organisms.
P. acnes is so far the only microorganism isolated from
sarcoid lesions by bacterial culture [13,14]. P. acnes is an
anaerobic, non-spore-forming, gram-positive rod bacterium
indigenous to the skin and mucosal surfaces. A series of
Japanese studies has provided accumulating evidence for a
role of P. acnes in sarcoidosis. In this review, we propose
mechanisms of granuloma formation in response to this
indigenous bacterium in subjects with sarcoidosis on the
basis of our results obtained using histopathological and
experimental approaches, and introduce a new concept of
endogenous infection caused by hypersensitivity to indigen-
ous bacteria.2. Bacterial culture
The lung and its draining lymph nodes are the organs most
commonly affected by sarcoidosis. As the lung constantly
encounters airborne substances, including pathogens, many
researchers have considered infection to trigger sarcoidosis
and have, thus, tried to identify possible causative transmis-
sible agents and their contribution to the mechanism of
sarcoid granuloma formation [15,16].
In the late 1970s, a large Japanese research project, con-
ducted by many clinicians and microbiologists with support
by a grant from the Japanese Ministry of Health, was orga-
nized to seek the pathogens responsible for sarcoidosis.
Extensive trials were performed to isolate microorganisms,
including bacteria, viruses, and fungi, from tissue samples
(in particular biopsied lymph nodes) affected by sarcoidosis.
Only P. acnes and no other microorganism was isolated from
the large number of samples [13]. P. acnes was isolated from
cultures of biopsy samples of 31 (78%) of 40 lymph nodes
from 40 patients with sarcoidosis [14], whereas this indigen-
ous bacterium was also isolated from 20% of 141 control
lymph nodes from patients with diseases other than sarcoi-
dosis. The study was repeated twice to confirm that the initial
samples had not been contaminated by cutaneous P. acnes
during biopsy, and the results of both studies were identical.
Ishige et al. cultured peripheral lung tissue and various lymph
nodes obtained from patients with diseases other than sarcoi-
dosis [17]. P. acneswas isolated from 24 of 43 lungs and eight of 11
mediastinal lymph nodes, mostly in pure culture. P. acnes was
isolated from 10 of 20 gastric and three of 12 intestinal lymph
nodes; intestinal bacteria were also numerous. P. acnes was, in
general, the only species isolated from these tissues. The
number of P. acnes cells isolated was usually not more than
500 CFU/g in the lungs and lymph nodes. Of 43 lungs from
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high numbers of P. acnes cells. Random amplified polymorphic
DNA analysis was used to compare the DNA of 45 isolates of P.
acnes from these patients, 39 isolates from sarcoid lymph nodes,
and 67 isolates from normal skin, conjunctiva, and intestine. The
P. acnes strains in the lung andmediastinal lymph nodes differed
genetically from those in the skin. Therefore, contamination
from the skin during operative or culture procedures seems
unlikely. These findings suggest that P. acnes normally resides in
peripheral lung tissue and mediastinal lymph nodes.
Studies of cell-invading P. acnes are essential for linking
this indigenous bacterium to the cause of sarcoidosis because
infectious granulomas are commonly caused by intracellular
pathogens. Furukawa et al. examined cell invasiveness and
the serotype of P. acnes isolates from lymph nodes affected by
sarcoidosis, together with isolates from non-sarcoid tissue
obtained from lymph nodes, lungs, prostate, skin, conjunc-
tiva, and intestine [18]. The invasiveness of these P. acnes
isolates into HEK293T cells was examined by cell-invasion
assays conducted according to the method described by Cue
and Cleary [19] and intracellular localization of the invasive
isolates was confirmed by electron microscopy. Cell invasive-
ness was found in 14 (40%) of 35 sarcoid isolates and 65 (51%)
of 127 non-sarcoid isolates. The proportion of invasive
isolates did not differ between isolates from sarcoid and
non-sarcoid tissues. The whole-bacterium enzyme-linked
immunosorbent assays with serotype-specific antibodies dis-
criminated the serotype of all 162 isolates (112 strains of
serotype I and 50 strains of serotype II). The proportion of the
two serotypes did not differ between sarcoid and non-sarcoid
tissues. Cell invasiveness was found in 79 (71%) of 112
serotype I isolates and in none of the 50 serotype II isolates.3. Polymerase chain reaction
Some investigators used PCR assays to detect mycobacterial
DNA in samples of affected tissue from patients with sarcoi-
dosis [20–22], but others did not [23–25]. Quantification of
bacterial genomes detected in sarcoid lesions is essential for
clarifying the etiologic correlation between lesions and
bacteria detected therein, because a very small amount of
bacteria or bacterial DNA can be detected, even in conditions
of latent infection or contamination with no etiologic
correlation.
Ishige et al. used quantitative PCR to search for bacterial
genomes of P. acnes, P. granulosum, and M. tuberculosis in
histological sections of lymph nodes from patients with
sarcoidosis, tuberculosis, or gastric cancer [26]. They exam-
ined lymph node biopsy samples from 15 patients with
sarcoidosis and 15 patients with tuberculosis lymphadenitis.
As controls, they examined 15 lymph nodes from 15 patients
with gastric cancer without metastasis who underwent
surgery (Fig. 1A). Genomes of M. tuberculosis were found in
samples from all 15 patients with tuberculosis, three patients
with sarcoidosis, and one control sample. Genomes of P. acnes
were found in 12 (80%) patients with sarcoidosis, two tuber-
culosis patients, and three controls. The difference in the
estimated number of P. acnes genomes between individuals
with and without sarcoidosis was similar to the number ofM. tuberculosis genomes between people with and without
tuberculosis. Biopsy samples from the three patients with
sarcoidosis but without P. acnes contained many P. granulosum
genomes. These findings suggest that propionibacteria
resided in or proliferated ectopically in sarcoid lesions,
whether or not there was a connection with the disease.
Propionibacteria are more likely than mycobacteria to cause
sarcoidosis.
An international collaborative study evaluated the possi-
ble etiologic link between sarcoidosis and the suspected
bacterial species [8]. Formalin-fixed and paraffin-embedded
sections of biopsy samples of lymph nodes from 108 patients
with sarcoidosis and 65 patients with tuberculosis, together
with 86 control samples, were collected from two institutes in
Japan and three institutes in Italy, Germany, and England
(Fig. 1B). Genomes of P. acnes, P. granulosum, M. tuberculosis,
M. avium subsp. paratuberculosis, and Escherichia coli (as con-
trol) were estimated by quantitative real-time PCR. Either P.
acnes or P. granulosum was found in all but two of the sarcoid
samples. M. avium subsp. paratuberculosis was not found in
any sarcoid sample. M. tuberculosis was found in only 0–9% of
the sarcoid samples, but in 65–100% of the tuberculosis
samples. In sarcoid lymph nodes, the total numbers of
genomes of P. acnes or P. granulosum far exceeded those of
M. tuberculosis. P. acnes or P. granulosum was found in 0–60% of
the tuberculosis and control samples, but the total numbers
of genomes of P. acnes or P. granulosum in these samples were
lower than those found in sarcoid samples. Propionibacteria
spp. are more likely than Mycobacteria spp. to be involved in
the etiology of sarcoidosis, not only in Japanese but also in
European patients with sarcoidosis.4. In situ hybridization
In situ localization of P. acnes genomes in sarcoid lymph nodes
may help to elucidate an etiologic link between sarcoidosis
and this indigenous bacterium. Formalin-fixed and paraffin-
embedded biopsy samples of lymph nodes from nine patients
with sarcoidosis, nine patients with tuberculosis, and nine
patients with nonspecific lymphadenitis (controls) were exam-
ined by quantitative real-time PCR (QPCR) for P. acnes and by
in situ hybridization (ISH) using catalyzed reporter deposition
(CARD) for signal amplification with digoxigenin-labeled oligo-
nucleotide probes that complemented 16 S rRNA of P. acnes [27].
The signals per 250 mm2 of tissue sections were counted from
inside and outside sarcoidosis and tuberculosis granulomas
and from control lymph nodes. The number of genomes
determined by QPCR was examined for correlation with the
mean signal count by ISH with CARD. In sarcoid samples, many
signals were detected in the cytoplasm of some epithelioid cells
in granulomas (Fig. 2A). The mean signal counts were higher in
granulomatous areas than in other areas of sarcoid lymph
nodes. The correlation between the QPCR and ISH with CARD
results was significant (r¼0.86, po0.001). The accumulation of
P. acnes genomes in and around sarcoid granulomas suggests
that this indigenous bacterium is related to the cause of
granulomatous inflammation in sarcoidosis.
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Fig. 1 – Numerous genomes of P. acnes are found in sarcoid samples. Quantitative polymerase chain reaction (PCR) of
bacterial DNA in lymph nodes; (A) from patients with sarcoidosis (Sar), tuberculosis (Tbc), and gastric cancer (Cont) and (B)
from Japanese and European patients with sarcoidosis. The horizontal dotted lines show the detection threshold and
samples with results below this line were considered negative. Biopsy samples from the 3 patients with sarcoidosis but
without Propionibacterium acnes (as indicated by large black dots) all contained many P. granulosum strains. PA: P. acnes, PG: P.
granulosum, MT: Mycobacterium tuberculosis, and EC: Escherichia coli.
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Granulomatous reactions are a defense mechanism that the
body uses to fight off poorly degradable antigens. To evaluate
the pathogenic role of P. acnes, Negi et al. screened for this
indigenous bacterium in sarcoid and non-sarcoid tissues using
immunohistochemical methods with novel P. acnes-specific
monoclonal antibodies that react with cell membrane-bound
lipoteichoic acid (PAB antibody) and ribosome-bound trigger
factor protein (TIG antibody). They examined formalin-fixed
and paraffin-embedded samples of lungs and lymph nodes
from 196 patients with sarcoidosis and corresponding control
samples from 275 patients with non-sarcoidosis diseases. The
samples were mostly from Japanese patients; however, 64
lymph node samples were from German patients [28].
Immunohistochemistry with the PAB antibody revealed small
round bodies within sarcoid granulomas in 20/27 (74%) video-
assisted thoracic surgery lung samples, 24/50 (48%) transbron-
chial lung biopsy samples, 71/81 (88%) Japanese lymph node
samples, and 34/38 (89%) German lymph node samples. The PAB
antibody did not react with non-sarcoid granulomas in any of
the 45 tuberculosis samples or the 34 samples with sarcoid
reaction. In sarcoid granulomas with many small round bodies,the cytoplasm of some granuloma cells was filled with small
round bodies, consistent with the intracellular proliferation of
the bacterium (Fig. 2B). In many sarcoid granulomas, a few small
round bodies with occasionally degraded or large-sized features
were scattered in some of the granuloma cells. The amount of
these small round bodies varied from each granuloma in
identical sarcoid samples, as well as from each sarcoid tissue
sample. The appearance of small round bodies detected by the
PAB antibody within sarcoid granulomas did not differ between
lungs and lymph nodes (Fig. 3).
In non-granulomatous areas, small round bodies detected by
the PAB antibody were found in alveolar macrophages of lungs
and paracortical macrophages of lymph nodes from many
sarcoid and some non-sarcoid patients. In the lymph nodes,
paracortical macrophages with many small round bodies
detected by the PAB antibody (Fig. 4A) were observed in 26
(22%) of 119 sarcoid samples and in 18 (11%) of 165
non-sarcoid samples. The frequency was significantly higher in
the sarcoid samples. Such small round bodies were observed in
lymphatic endothelial cells in a few samples of sarcoid lymph
nodes (Fig. 4B). In the lungs, alveolar macrophages with many
small round bodies detected by the PAB antibody were found in
Fig. 2 – Genomes and antigens of P. acnes are localized in sarcoid
granulomas. In situ hybridization using catalyzed reporter
deposition for signal amplification with digoxigenin-labeled
oligonucleotide probes that complemented the 16 S rRNA of
Propionibacterium acnes (A). Many signals were detected in
the cytoplasm of sarcoid granuloma cells.
Immunohistochemistry with a P. acnes-specific monoclonal
antibody (PAB antibody) that reacts with cell membrane-
bound lipoteichoic acid of the bacterium (B). Many small
round bodies detected by the PAB antibody are shown
intermingled with many lymphocytes in an immature
granuloma (), but only a few are observed in a mature
granuloma () of the sarcoid lymph node. Most of the P. acnes
are present within the granuloma, but some are present
outside of the granuloma (as indicated by the arrow).
Fig. 3 – Localization of P. acnes within and around sarcoid
granulomas of the lung. In the lung sarcoid granuloma lesion
surrounded by prominent inflammatory cell infiltration, small
round bodies are detected by the Propionibacterium acnes-
specific monoclonal antibody (PAB), not only in the granuloma
cells but also in some of the inflammatory cells. As shown in
higher magnification (inset) of the area indicated by the arrow,
some swollen macrophages in the immature granuloma are
filled with many small round bodies detected by the PAB
antibody.
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 5 6 – 6 86028 (36%) of 77 sarcoid samples and in 18 (16%) of 110 non-sarcoid
samples. The frequency was significantly higher in sarcoid
samples. Such alveolar macrophages occasionally contained
one or a few large spheroidal bodies detected by the PAB
antibody that were acid-fast with Fite staining and also reacted
with the TIG antibody.
Hamazaki–Wesenberg (HW) bodies frequently appear in sar-
coid lymph nodes, although these bodies are not specific to
sarcoidosis [29–31]. The large spheroidal acid-fast HW bodies,
which were found in 50% of sarcoid and 15% of non-sarcoid
lymph node samples, reacted with both PAB and TIG antibodies.Electron microscopy revealed that these HW bodies had a single
bacterial structure and lacked a cell wall with occasional protru-
sions from the body (Fig. 5). Immunoelectron microscopy
revealed that the immunoreactive products of the PAB antibody
and TIG antibody were differentially distributed in the outer and
inner areas of the HW bodies, respectively (Fig. 6). The localiza-
tion of cell membrane-bound lipoteichoic acid detected by the
PAB antibody and ribosome-bound trigger factor detected by the
TIG antibody suggests that HW bodies might not be phagolyso-
somally degraded products of P. acnes. Instead, they are rather
intact forms of the intracellular bacteria because the original
distribution pattern (plasmalemmal and protoplasmic localiza-
tion, respectively) of these bacterial components was preserved
in terms of the morphologic structure of the bacterium. Further-
more, conventional electron microscopy revealed that these
bodies lack a cell wall structure and occasionally exhibit protru-
sions from the body that appear to be yeast-like proliferation
features (not mitotic, but sprouting or branching), characteristic
of cell wall-deficient (L-form) bacteria (Fig. 5). HW bodies may be
cell wall-deficient forms of P. acnes.
The PAB antibody seems to be appropriate for detecting
cell wall-deficient forms of P. acnes because an epitope of
lipoteichoic acid detected by this antibody is more exposed in
cell wall-deficient forms than in conventional forms of the
bacterium. The high frequency and specificity of P. acnes
detected by the PAB antibody within sarcoid granulomas
suggests an etiologic link between sarcoidosis and this
indigenous bacterium. The PAB antibody may be useful for
diagnosing sarcoidosis caused by P. acnes, when reactivity is
detected in idiopathic granulomas.
Histopathological analysis with the PAB antibody led us to
formulate a hypothesis for the mechanism of granuloma forma-
tion in sarcoidosis (Fig. 7). P. acnes causes latent infection and
Fig. 4 – Intracellular proliferation of latent P. acnes in
macrophages of sarcoid lymph nodes. A cluster of some
swollen macrophages filled with many small round bodies
detected by the Propionibacterium acnes-specific monoclonal
antibody (PAB) is occasionally found in paracortical areas of
sarcoid lymph nodes (A). The arrow indicates a large-
spheroidal body similar to Hamazaki–Wesenberg bodies.
Some of the small round bodies detected by the PAB
antibody were observed in lymphatic endothelial cells
adjacent to sarcoid granulomas of the lymph node (B).
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 5 6 – 6 8 61persists in macrophages. HW bodies are dormant and cell wall-
deficient forms of P. acnes. This dormant form of P. acnes can be
activated endogenously under certain environmental conditions
and proliferate in cells at the sites of latent infection. Small
round bodies proliferating in macrophages are infective forms of
P. acnes. When these bodies are released frommacrophages, they
infect other cells or organs via the lymph and blood streams.
Sarcoid granulomas are formed as a host defense mechanism at
sites of activated bacteria proliferating intracellularly in patients
with hypersensitive immune responses to P. acnes to prevent the
spread of the infectious agent.6. Hypersensitivity to P. acnes antigens
Host factors may be more critical than agent factors in the
etiology of sarcoidosis, as suggested by the Kveim testphenomenon [32], in which an intracutaneously injected
suspension of sarcoid tissue causes sarcoid granulomas in
patients with sarcoidosis, but not in healthy people or
patients with other diseases. The inflammatory response in
sarcoidosis involves many activated T cells and macrophages
[33], with a pattern of cytokine production in the lungs that is
consistent with a helper T-cell type 1 (Th1) immune response
triggered by undefined antigen(s) [34]. If a propionibacterium
caused a particular case of sarcoidosis, it is likely that an
antigen arising from the bacterium gave rise to a Th1
immune response in the subject.
Ebe and colleagues searched for propionibacterial antigens
that evoked cellular immune responses only in patients with
sarcoidosis [11]. For this purpose, a lgt11 genomic DNA library of
P. acnes was screened with sera from patients with sarcoidosis,
because high levels of serum antibodies against the antigen
usually accompany such an immune response. Of 180,000
plaques screened, two clones coded for an identical recombi-
nant protein, RP35, were recognized by sera. RP35, a recombi-
nant protein of 256 amino acid residues with a calculated
molecular mass of 28,133 Da, is a fragment (C-terminal region)
of the P. acnes trigger factor, which has 529 amino acid residues
and a calculated molecular mass of 57,614 Da. The C-terminal
sequence (Asp-463 to Lys-529) seems to be unique to P. acnes,
with no similarity to sequences of other bacterial proteins
deposited in the Swiss-Prot database. Conformational analysis
of the region from Ser-491 to Lys-529 at the C terminus revealed
it to be highly antigenic. RP35 caused sarcoidosis-specific pro-
liferation of peripheral blood mononuclear cells (PBMCs) from
nine (18%) of 50 patients with sarcoidosis (Fig. 8).
Recently, Furusawa et al. [35] reported that interleukin (IL)-2
secretion from PBMCs after stimulation with viable P. acnes is
higher in patients with sarcoidosis than in control subjects. IL-2
and IL-12 mRNA expression levels in PBMCs after stimulation
with P. acnes were also higher in patients with sarcoidosis than
in control subjects. In contrast, IL-17 mRNA expression in
PBMCs is lower in patients with sarcoidosis than in control
subjects. The responses of the two groups to stimulation with
M. tuberculosis antigens such as Bacille de Calmette et Gue´rin
(BCG) or ESAT-6 recombinant protein were not significantly
different. Sarcoidosis may arise from an imbalance of Th1/Th17
immune responses to viable P. acnes.
Additional evidence of the hypersensitivity of sarcoid
patients to P. acnes was obtained in studies of bronchoalveolar
lavage (BAL) cells. When stimulated with a crude extract of P.
acnes with pyridine, BAL cells from patients with sarcoidosis
proliferated more than BAL cells from healthy subjects or
from patients with lung cancer [36]. IL-2 production and IL-2
receptor expression of BAL cells stimulated by the P. acnes
antigen was greater in sarcoidosis patients than in healthy
subjects or patients with other lung diseases [37]. P. acnes
DNA was detected in BAL cells from 21 (70%) of 30 sarcoid
patients and 7 (23%) of 30 control patients with other lung
diseases [38]. In situ signals of P. acnes DNA were detected in
the cytoplasm of a few alveolar macrophages among the BAL
cells from sarcoid patients, but from no other kinds of BAL
cells, including alveolar lymphocytes and neutrophils.
Gallium-67 uptake by lung parenchyma was found in about
half of the 30 sarcoid patients with P. acnes DNA, but in none
of the other sarcoid patients [38].
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Fig. 6 – Morphological demonstration of cell-wall-deficient P. acnes
in sarcoid lymph nodes. Immunoelectron-microscopic analysis
with Propionibacterium acnes-specific monoclonal antibodies
(PAB and TIG antibodies) suggests Hamazaki–Wesenberg (HW)
bodies may be cell-wall-deficient P. acnes.
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Fig. 7 – Hypothesized mechanism of sarcoid granuloma
formation caused by P. acnes. Intracellular proliferation of
latent Propionibacterium acnes in macrophages triggers
granuloma formation in patients with hypersensitivity to
this indigenous bacterium.
Fig. 5 – Hamazaki-Wesenberg (HW) bodies in sarcoid lymph nodes. HW bodies are large and spheroidal in shape with a
yellow–brown color (green arrow) with hematoxylin and eosin staining (A). These bodies are strongly acid-fast with Fite
staining (B). HW bodies with one-by-one protrusions (C) (black arrows) are rarely found in sinus macrophages of sarcoid
lymph nodes. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.)
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A single intravenous injection of P. acnes into mice leads to the
development of granulomas in the liver [39–41], but not in the
lung. Pulmonary granulomas can be induced, however, by an
intravenous injection of P. acnes into sensitized rats [42] and
rabbits [43]. In these two studies of experimental pulmonary
granulomas, heat-killed P. acnes was used as sensitizer, and
challenge by a single intravenous injection of the bacterium
was essential for granulomas to form in the lungs.P. acnes trigger factor protein (RP35) or heat-killed P. acnes
causes pulmonary granulomas in some (25–57%) mice sensi-
tized with the protein and complete Freund’s adjuvant
[44]. An intravenous injection of P. acnes as a challenge
was not essential for granulomas to form in the lungs.
Granulomas were scattered throughout the lungs, especially
in subpleural areas. The granulomas were composed of a
core of epithelioid cells intermingled with a few and sur-
rounded by numerous mononuclear cells (Fig. 9C). The
detection frequency of pulmonary granulomas did not differ
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Fig. 8 – P. acnes trigger factor causes sarcoidosis-specific immune response in some patients. Response of peripheral blood
mononuclear cells (PBMC) to recombinant trigger factor protein (RP35) from Propionibacterium acnes and purified protein
derivative (PPD) from Mycobacterium tuberculosis. The horizontal bars show, from bottom to top, the 25th percentile, median,
and 75th percentile, respectively. The dotted lines show the threshold, set at the meanþ3 SD of 32 control samples.
A
B C
Fig. 9 – Pulmonary granulomatosis caused by sensitization
with P. acnes. Histological and macroscopic features (A and
B) of the lungs from a rabbit with experimental pulmonary
granulomatosis induced by sensitization with
Propionibacterium acnes trigger factor protein and adjuvant.
Whitish lesions are distributed throughout and are
especially prominent in the subpleural and interlobular
areas (A). Multiple non-caseating epithelioid cell
granulomas are accompanied by surrounding lymphoid cell
infiltration with alveolitis (B). A histological feature (C) is a
non-caseating epithelioid cell granuloma observed in a
mouse with experimental pulmonary granulomatosis
induced by sensitization with P. acnes trigger factor protein
and adjuvant.
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killed P. acnes.
This experimental protocol may provide a satisfactory
model of sarcoidosis. First, hypersensitivity to P. acnes trigger
factor, experimentally induced as described earlier in the
text, has been reported in some patients with sarcoidosis.
Second, situations resembling intravenous challenges with
P. acnes are rare in humans, and sarcoidosis can start in
asymptomatic persons without evidence of septicemia.
Experimental models of allergic diseases, e.g., encephalo-
myelitis [45], thyroiditis [46], and orchitis [47], have been
produced by immunizing animals with self-antigens (myelin
basic protein, thyroglobulin, and testicular homogenate,
respectively) emulsified in complete Freund’s adjuvant,
which is essential for the experiment. Autoimmune inflam-
matory lesions are induced in this way only in organs from
which the self-antigens used for the sensitization originated.
In the animal model of sarcoidosis, sensitization of mice with
P. acnes trigger factor protein or heat-killed P. acnes in
complete Freund’s adjuvant induces granulomatous inflam-
mation confined to the lungs. This finding suggests that such
antigens from P. acnes exist in the lungs of mice even before
the experiment.
Similar to the results obtained by bacterial culture of
human samples from lung and lymph nodes, P. acnes was
cultured from lungs, liver, and lymph nodes from some of the
untreated normal mice, and culture was most often success-
ful with the lung samples. There was an unexpected con-
cordance in the rate (33%) of culture from normal lungs and
the frequency of detection of pulmonary granulomas in mice
sensitized with the trigger factor protein. The observed
concordance suggests that mice without granulomas may
have been free from P. acnes in the normal indigenous flora of
their lungs before and during the experiment.
Using the same experimental protocol with rabbits bred in
a conventional environment, rabbits sensitized with the
P. acnes trigger factor antigen developed more severe and
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Fig. 10 – Prevention of experimental models of sarcoidosis by antibiotics. Prevention of pulmonary granulomatosis in mice and
rabbits sensitized with Propionibacterium acnes trigger factor (TIG) antigen by administration of antibiotics before and during
the experiments.
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In fact, severe granulomatous inflammation that developed
could even be identified macroscopically (Fig. 9A and B). Th1
immune response to the P. acnes trigger factor protein might
have caused pulmonary granulomas at the sites of P. acnes
infection. Indeed, administration of antibiotics (azithromycin
in mice and minocycline in rabbits) before and during the
experiments prevented granuloma formation in these experi-
mental models (Fig. 10).
Nishiwaki et al. further examined the mechanism of
pulmonary granulomatosis caused by sensitization with heat-
killed P. acnes [48], using a similar experimental protocol as used
in a previous study [44]. In their study, P. acnes was identified in
normal murine alveolar cells by immunostaining with a
P. acnes-specific monoclonal antibody (PAB antibody). P. acnes
was taken up by lung cells, and the P. acnes-bearing cells
expressed F4/80 rather than CD11c or DEC205, which is con-
sistent with the ability of macrophages to phagocytose and
deliver antigens to dendritic cells in the lung. As far away as the
end of the airway, airborne organisms are impacted and
eliminated by mechanical defenses, including mucociliary
clearance and coughing. Nevertheless, a small number of
P. acnes might escape this system and reside on the alveolar
surface. P. acnes genomes were detected in normal pulmonary
lymph nodes, as well as the lungs, and lymphocytes from
lymph nodes showed P. acnes-specific proliferation, suggesting
that these cells had already been exposed to P. acnes by lung-
derived antigen-presenting-cells and had established a memory
response. In addition, these results indicate that P. acnes were
continuously transported to pulmonary regional lymph nodes
in the steady state. Because of this constant delivery of antigens
to pulmonary lymph nodes for a long period, a small number of
indigenous P. acnes in the normal lung would be sufficient to
produce a specific immune response; however, it would not be
sufficient for the formation of a steady-state granuloma.
Although mycobacterial, atypical mycobacterial, and other
propionibacterial antigens are potential candidate endogenous
microorganisms that trigger pulmonary granuloma formation,
genomic analyses revealed an absence of these organisms in
the lungs of specific-pathogen-free C57BL/6 mice.The adoptive transfer of P. acnes-sensitized lymph node CD4þ
T cells into naı¨ve mice resulted in granulomatous changes in the
lung, indicating that extrapulmonary lymph node CD4þ T cells
primed with P. acnes can interact with pulmonary resident cells
via the circulation and induce granuloma formation in the
normal lung. Therefore, it was hypothesized that a continuous
supply of P. acnes-sensitized T cells could lead to chronic
pulmonary granuloma formation and, consequently, we per-
formed continuous remote sensitization of normal mice with
P. acnes. These mice exhibited distinct pulmonary granulomas,
distributed in lymph-rich spaces such as the subpleural, peri-
bronchial, and perivascular areas, and had typical cellular
components of granuloma and preferential Th1 cytokine expres-
sion. These features are similar to those of pulmonary sarcoi-
dosis. In addition, the ratio of CD4 to CD8 BAL lymphocytes was
elevated in the group immunized twice, and serum calcium
levels were also increased. Thus, the characteristics of this
P. acnes-immunization model, without any direct exposure of
an antigen to the lung, showed several similarities to those of
sarcoid patients.
That study also examined whether changes in the number of
pre-existing P. acnes cells in the lung affected pulmonary gran-
uloma formation. As expected, preloading of P. acnes exacerbated
pulmonary disorders, whereas reduction of the P. acnes popula-
tion by antimicrobial treatment reduced the number of pulmon-
ary lesions. These findings suggest a pivotal role of normally
localized P. acnes in the formation of pulmonary granuloma by
extrapulmonary P. acnes sensitization, as well as the potential
clinical usefulness of antimicrobial eradication targeting lung-
indigenous P. acnes for the treatment of pulmonary granuloma-
tosis induced by a similar pathogenesis.8. Etiology of sarcoidosis
In the past, once the germ theory of disease was accepted,
microbes were considered to be pathogens if they met the
stipulations of Koch’s postulates. Although there are many
microbes, most human infections are caused by only a few.
Some microbes have been classified as pathogens although
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microbes have been classified as nonpathogenic although they
cause disease in certain hosts. For these reasons, in a redefini-
tion of the concepts of virulence and pathogenicity of
microbes, Casadevall and Pirofski suggested a classification
system for pathogens based on their ability to cause damage
as a function of the host’s immune response [49]. Koch’s
postulates for exogenous infection cannot be applied to dis-
eases caused by endogenous bacteria. An endogenous infec-
tion is a disease caused by indigenous microorganisms.
According to the classification system suggested by Casadevall
and Pirofski, an endogenous infection, which does not cause
any lesions under normal immune conditions, can be classi-
fied into 3 major categories (Fig. 11). Opportunistic infections,
e.g., pneumonia caused by Pneumocystis jiroveci, are well known
to be associated with immunodeficiency in AIDS patients.
Combination-type infections, e.g., Candida and Aspergillus,
not only cause opportunistic infections, but may also cause
hypersensitivity pneumonitis. The hypersensitivity type of
endogenous infections does not cause any tissue damage until
a hypersensitive immune response is triggered. P. acnes as a
cause of sarcoidosis can, therefore, be classified within the
group of endogenous diseases that results from
hypersensitivity.
P. acnes is the most common commensal bacterium in the
lungs and lymph nodes from subjects without sarcoidosis
[17]. Some P. acnes is found in 20% of non-sarcoid lymphFig. 11 – Three major categories of endogenous infection in t
microorganisms.
Fig. 12 – Hypothesized mechanism of systemic sarcoid granulomanodes by bacterial culture [17], in 15% of non-sarcoid lymph
nodes by PCR [26], and in 18% of non-sarcoid lung samples
and 22% of non-sarcoid lymph node samples by immunohis-
tochemistry [28]. Occasional detection of intracellular P. acnes
in non-granulomatous areas of the lungs and lymph nodes
from non-sarcoid patients suggests that latent infection and
endogenous reactivation of this indigenous bacterium occurs
in these organs, even in patients without sarcoidosis. Sarcoi-
dosis involves many organs, and the lungs and mediastinal
lymph nodes are the organs involved at the highest frequency
[50]. Commensalism of P. acnes in these organs may explain
why they are frequently involved in sarcoidosis.
P. acnes, an indigenous low-virulence bacterium, can cause
latent infection in the lungs and lymph nodes and persist in a
cell wall-deficient form. This dormant form of P. acnes can be
activated endogenously under certain environmental condi-
tions and then proliferate in cells at the site of the latent
infection. In patients hypersensitive to this endogenous
bacterium, granulomatous inflammation is triggered by intra-
cellular proliferation of the bacterium. Some proliferating
bacteria may escape from isolation by the granuloma and
spread to other organs via the lymph and blood streams. The
spread of infective P. acnes might cause a new latent infection
in systemic organs, e.g., eyes, skin, and heart. A latent
infection established in certain systemic organs will be
reactivated simultaneously by the next triggering event,
resulting in the onset of systemic sarcoidosis (Fig. 12).he classification system of diseases caused by indigenous
formation caused by P. acnes. CNS: central nervous system.
Latent infection
(cell wall-deficient form)
Eradication of 
latent bacteria
Prevention of 
endogenous activation Antibiotics
Endogenous activation
(Intracellular proliferation)
Prevention of 
intracellular proliferation
Suppression of 
Corticosteroidsallergic reaction
Granuloma formation
Environmental factors
Th1 hypersensitivity
Fig. 13 – Strategy for treating sarcoidosis caused by
Propionibacterium acnes.
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activation of a latent infection might lead to the spread of
infectious P. acnes, giving rise to a new latent infection, even
within the same organ. As long as such latent infection remains
in the organs, the process will be repeated whenever reactiva-
tion occurs under the requisite environmental conditions.
Relapsing sarcoidosis causes repetitive acute inflammation
and post-inflammatory scars in the affected organs, which
results in the progression of sarcoidosis through tissue damage
and functional disorder in the affected organ.
Sarcoidosis is most likely the result of a complex interac-
tion between infection, immunity, and allergic reaction.
There are three conditions essential to the development of
sarcoidosis caused by P. acnes: (1) latent infection with cell
wall-deficient P. acnes, (2) endogenous activation of dormant
P. acnes triggered by certain environmental factors, and (3) a
hypersensitive Th1 immune response towards the intracel-
lular proliferation of P. acnes. The formation of sarcoid
granulomas might be induced by a Th1 immune response
to one or more antigens of P. acnes, proliferating in the
affected organ or tissue in an individual with a hereditary
or acquired abnormality of the immune system.
Endogenous reactivation of latent bacteria is well known to
occur in tuberculosis, which sharesmany common featureswith
sarcoidosis, i.e., histopathological features, as well as pathogenic
features. Many cases of adult tuberculosis are caused by endo-
genous activation of a latent tuberculosis infection [51,52].
Tuberculosis and sarcoidosis are adverse effects of anti-tumor
necrosis factor-a drugs administered to patients with rheuma-
toid arthritis [53,54]. Anti-tumor necrosis factor-a treatment is
thought to reactivate a latent tuberculosis infection [55]. In the
same manner, latent P. acnes might be reactivated by anti-tumor
necrosis factor-a treatment, resulting in sarcoidosis in certain
susceptible subjects among these patients.9. Treatment of sarcoidosis
Immunosuppressive therapy, mainly corticosteroids, has been
used for sarcoidosis for more than 50 years, but the long-term
effects of steroidal treatment in chronic sarcoidosis are still
disputed [3]. Furthermore, high relapse rate after treatment
and side effects of long-term use are often a clinical challenge
[56]. Steroids suppress the allergic reaction, thereby providing
therapeutic effects. Interference of the inflammatory process by
these immunosuppressive drugs, however, may impede the
formation of granulomas, which function to curtail the spread
of P. acnes infection.
Antibiotics kill the bacteria proliferating in cells, as well as
prevent endogenous activation of latent bacteria. Long-term
administration of antibiotics may, therefore, be effective for
patients with progressive sarcoidosis by preventing inflammatory
relapses caused by reactivation of latent bacteria (Fig. 13). If latent
bacterial infections that persist in organs can be eradicated by
treatment with antibiotics, complete remission of sarcoidosis
may be achieved. However, complete eradication of latent bac-
teria might be difficult to achieve through the conventional use of
antibiotics, as in the case of pulmonary tuberculosis.
Another approach for treating sarcoidosis is specific sup-
pression of the hypersensitivity to P. acnes antigens responsiblefor granuloma formation, e.g., the trigger factor protein. Recent
advances in the modulation of epitope-specific immune
responses by synthetic peptides might help to improve the
treatment of sarcoidosis.
Minocycline is the first-choice antibiotic for patients with
acne vulgaris caused by P. acnes. In an observational study,
Bachelez and colleagues [57] reported the possible benefits of
tetracyclines, to which P. acnes is sensitive, for the treatment of
chronic forms of cutaneous sarcoidosis. The authors treated 12
patients with biopsy-proven cutaneous sarcoidosis with 200mg
daily minocycline over a median 12-month period. With a
median follow-up of 26 months, the authors noted complete
and partial responses to treatment in eight and two patients,
respectively. The mean time to reach a maximal response was
3.2 months. Of the eight patients who had complete response,
minocycline could be withdrawn in seven patients, three of
whom experienced recurrent lesions and received further treat-
ment with 200mg daily doxycycline. Complete remission was
maintained for a mean of 15.3 months. Regression of pulmonary
infiltrates and mediastinal lymphadenopathy was noted in the
two patients with concurrent pulmonary involvement.
The results of a nationwide questionnaire survey, performed
by a Japanese research group in 2005 (reported in Japanese),
indicated that antibiotic therapy was effective in 43% of patients
with sarcoidosis treated with several kinds of antibiotics, includ-
ing minocycline, doxycycline, and clarithromycin. Baba and
colleagues [58] used minocycline and clarithromycin for therapy
against worsening of multiple endobronchial mass lesions, given
the possible roles of P. acnes in the pathophysiology of sarcoidosis
and the uncertainty of the long-term effects of corticosteroids.
The lesions were worsening before the antibiotic therapy was
initiated; thus, the noted improvements appeared to be due to
the therapy. Park and colleagues [59] reported the first case of
ocular and ocular adnexal sarcoidosis treated with minocycline.
The patient in their report demonstrated complete and
recurrence-free response of lacrimal gland and choroidal lesions,
as well as parotid granulomas and pulmonary infiltrates after 3
months of minocycline therapy. Miyazaki and colleagues [60]
reported the regression of nodular lesions of muscular sarcoi-
dosis during minocycline treatment with decreased levels of
angiotensin-converting enzyme, lysozyme, and soluble IL-2
receptor. The effectiveness of minocycline for muscular
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 5 6 – 6 8 67sarcoidosis in this case was confirmed when a prompt response
to minocycline therapy was repeatedly observed.
According to the studies described in this section, the
antimicrobial properties of tetracyclines are effective for
treating sarcoidosis. Many researchers have questioned the
antimicrobial role of tetracyclines because tetracyclines have
also anti-inflammatory properties, which were demonstrated
by in vitro studies and corroborated by clinical trials. Tetra-
cycline suppresses neutrophil migration and chemotaxis [61],
and minocycline inhibits T-lymphocyte activation and
proliferation [62]. Both minocycline and doxycycline obviate
granuloma formation in vitro [63]. Although it remains con-
troversial whether these antibiotics kill microbes or have only
an anti-inflammatory effect, the mechanisms of sarcoid
granuloma formation caused by P. acnes proposed in this
chapter suggest that these antibiotics have many roles in the
process of granuloma regression, including prevention of
events that trigger granuloma formation caused by intracel-
lular proliferation of the bacterium.
The Marshall protocol [64] is an eradication therapy for
intracellular bacteria established by Dr. Trevor Marshall. This
therapeutic protocol is a combination of minocycline plus
azithromycin or clindamycin, supported by the use of an
angiotensin receptor blocker to prevent Herxheimer reactions.
According to the results published by the Autoimmunity
Research Foundation in 2006, this therapy is effective in 62%
of patients with sarcoidosis. Information about the treatment
can be found at the study site, marshallprotocol.com, as well as
at autoimmunityresearch.org.Conflict of interest
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